Castle Biosciences, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Castle Biosciences, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Castle Biosciences, Inc. do? Business model and key facts
Get the full picture of Castle Biosciences, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees (FY): 784
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Stocks related to Castle Biosciences, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Castle Biosciences, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Castle Biosciences, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
